Business, energy, technology, markets and global industry news from Business News Today
Features & Analysis

Novartis paid $12bn for Avidity Biosciences. What does del-desiran’s Phase 3 failure do to the deal thesis?

Novartis AG has encountered an unusually expensive reminder of how quickly biotechnology acquisition economics can change once a pivotal trial reports. Delpacibart etedesiran, better known as del-desiran, failed to demonstrate a statistically significant improvement over placebo on the primary endpoint in the Phase 3 HARBOR trial in myotonic dystrophy type 1, only months after Novartis completed its acquisition of Avidity Biosciences for approximately $12 billion. Novartis shares subsequently suffered their worst one-day decline on record, with Reuters reporting a 10.9% fall that erased roughly $32 billion in market value.

The result matters because del-desiran was not an isolated early-stage experiment buried inside a diversified transaction. It was one of three antibody oligonucleotide conjugate programmes that Novartis highlighted when it completed the Avidity Biosciences acquisition in February 2026, describing the portfolio as capable of opening multi-billion-dollar opportunities and strengthening growth through the end of the decade. That makes the HARBOR result a test not merely of one drug but of how much clinical, strategic and financial value remains embedded in an acquisition whose price was justified partly by late-stage pipeline maturity.

Why does the HARBOR failure matter beyond a single myotonic dystrophy programme?

HARBOR evaluated del-desiran in myotonic dystrophy type 1, a progressive genetic neuromuscular disorder for which there are currently no approved disease-modifying treatments. The trial failed on video hand opening time, or vHOT, a novel measure intended to quantify hand myotonia. Novartis said secondary endpoints and exploratory analyses showed evidence of clinical activity and that safety findings were generally consistent with previously reported data, leaving open the possibility of further discussions with regulators rather than an immediate termination of the programme.

That distinction is important clinically because failure on a primary endpoint does not automatically prove that a biological mechanism is inactive. A study can miss because the magnitude of benefit is too small, because an endpoint does not adequately capture the treatment effect, because patient heterogeneity dilutes the signal, or because the therapeutic hypothesis itself is inadequate. Novartis has not yet provided enough information from the complete HARBOR dataset to determine which explanation carries the most weight, meaning any conclusion that the entire antibody oligonucleotide conjugate approach has failed would be premature.

The commercial consequence, however, arrives faster than the scientific answer. A pivotal miss removes a relatively visible path toward a potential launch and pushes the burden of proof onto secondary analyses, regulator discussions and the remainder of the acquired portfolio. For a transaction priced at roughly $12 billion, investors do not need every programme to succeed, but they do need enough high-value assets to survive clinical development and justify the acquisition premium.

Can the Avidity Biosciences acquisition still justify its $12 billion price?

Novartis did not buy Avidity Biosciences solely for del-desiran. The transaction added a muscle-targeted antibody oligonucleotide conjugate platform and three advanced programmes addressing myotonic dystrophy type 1, Duchenne muscular dystrophy amenable to exon 44 skipping and facioscapulohumeral muscular dystrophy. When the acquisition closed, Novartis explicitly presented those assets as a way to deepen its neuromuscular portfolio while potentially producing launches before 2030.

The remaining assets therefore matter disproportionately now. Delpacibart zotadirsen, or del-zota, is being developed for patients with Duchenne muscular dystrophy who have mutations amenable to exon 44 skipping. Novartis has filed the programme for accelerated approval and received United States Food and Drug Administration priority review. Delpacibart braxlosiran, or del-brax, is being developed in facioscapulohumeral muscular dystrophy, with Novartis planning discussions with the FDA after reporting positive Phase 1/2 biomarker findings.

Researchers evaluate antibody oligonucleotide conjugate (AOC) therapies for neuromuscular diseases as investors reassess the implications of the Phase 3 HARBOR trial setback for del-desiran and the broader value of Novartis' newly acquired AOC pipeline. Representative image.
Researchers evaluate antibody oligonucleotide conjugate (AOC) therapies for neuromuscular diseases as investors reassess the implications of the Phase 3 HARBOR trial setback for del-desiran and the broader value of Novartis’ newly acquired AOC pipeline. Representative image.

A favourable regulatory outcome for del-zota would therefore do more than create a new product opportunity. It would provide evidence that the Avidity platform can translate into a marketable therapy despite the HARBOR setback. Similarly, a credible development path for del-brax would strengthen the argument that Novartis acquired a reusable delivery technology rather than a single lead asset whose failure undermines the entire transaction.

The opposite scenario would be much more difficult. If additional Avidity-derived programmes encounter efficacy, safety or regulatory problems, the transaction could begin to resemble an acquisition whose strategic rationale weakened materially after closing. That would not necessarily lead immediately to an accounting impairment, but it would intensify questions about expected returns on the capital Novartis deployed.

Does del-desiran’s failure change the competitive race in myotonic dystrophy type 1?

The impact has already extended beyond Novartis. Reuters reported that Dyne Therapeutics fell about 18% after the HARBOR announcement, while Sarepta Therapeutics and PepGen also declined, reflecting concern that the failure could have implications for other experimental approaches in myotonic dystrophy. Dyne is particularly relevant because its DYNE-101 programme also uses video hand opening time among its clinical measures, creating an obvious point of comparison even though the underlying molecules and development strategies are not identical.

The read-through should nevertheless be treated cautiously. A disappointing result for one therapy does not establish that another company using a different construct, dosing strategy or delivery technology will fail. What HARBOR does change is the burden of interpretation. Competitors will face greater scrutiny over whether improvements in molecular biomarkers translate into functional outcomes that patients and regulators view as meaningful.

That can influence programme valuation well before competing pivotal trials finish. In rare neuromuscular diseases, investors often assign substantial value to early evidence because patient populations are small and commercial pricing can support meaningful revenue from relatively limited numbers of treated patients. A late-stage failure by a prominent programme therefore forces the market to reassess not only technical probability of success but also how aggressively it had priced the entire therapeutic category.

Why does the timing make the setback more consequential for Novartis?

Novartis is simultaneously managing patent-expiry pressure and attempting to sustain mid-single-digit growth through 2030. The company continues to guide for compound annual sales growth of 5% to 6% between 2025 and 2030, but the del-desiran setback arrived alongside other pipeline disappointments, including the failure of pelacarsen to deliver the expected cardiovascular outcome.

That is why the stock reaction was so severe relative to the failure of a single rare-disease programme. Investors were effectively repricing confidence in multiple layers of the future pipeline at the same time. The decline in Novartis’ market capitalisation substantially exceeded the acquisition price paid for Avidity Biosciences, showing that the market interpreted the news as potentially affecting the broader growth narrative rather than merely subtracting one drug’s risk-adjusted value.

The reaction does not prove that investors are correct about the eventual economic outcome. Pharmaceutical valuations can move sharply around pivotal trial events and later recover if other pipeline assets succeed. What it does show is that Novartis has less room for additional high-profile setbacks while maintaining the same level of confidence in its long-term growth assumptions.

What would begin rebuilding confidence in the Avidity strategy?

The first requirement is a fuller understanding of HARBOR. Novartis needs to establish whether secondary endpoints reveal a coherent clinical benefit, whether particular patient subgroups responded differently, whether exposure or disease stage affected outcomes and whether regulators see any viable path forward. A development programme preserved only through exploratory findings is fundamentally different from one where a missed primary endpoint masks consistent benefit across several clinically relevant measures.

The second requirement is progress elsewhere in the antibody oligonucleotide conjugate portfolio. An FDA decision on del-zota and clarity on del-brax could materially change how investors value the acquisition. Strong results would support the view that Avidity contributed a platform capable of producing multiple products, while additional setbacks would increasingly concentrate attention on the acquisition price.

For Novartis, therefore, the most important question is no longer whether HARBOR disappointed. That is already clear. The harder question is whether the $12 billion purchase of Avidity Biosciences still contains enough independent clinical shots on goal to produce returns that justify the transaction, and the next regulatory and clinical milestones may now carry considerably more financial significance than they did before HARBOR reported.